Neurogen cuts 70 jobs in restructuring

Neurogen is slashing 70 jobs in a restructuring that will focus company assets around its clinical programs. The drug developer is focused on insomnia, Parkinson's disease, restless legs syndrome and pain. Neurogen announced Monday that its president, Stephen R. Davis, had been appointed chief executive officer at the biotechnology company.

"As our clinical portfolio advances, we must allocate our resources to facilitate this growth," said Davis. "Our insomnia program holds the potential for significant differentiation and increased value as we seek to expand on the clinical profile we have seen thus far, suggesting improved objective and subjective measures of efficacy over currently available insomnia drugs. Aplindore remains on track for the commencement of Phase 2 studies in both Parkinson's disease and Restless Legs Syndrome."

- check out the release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."